Trial in Progress: An open-label, single-arm, phase 2 study to evaluate the efficacy and safety of loncastuximab tesirine in Chinese patients with relapsed/refractory diffuse large B-cell lymphoma
讲者：朱军
单位：北京大学肿瘤医院
Socazolimab在复发或转移性宫颈癌的疗效及安全性：一项I期临床试验及随后的扩展研究中的结果
讲者：吴令英
单位：中国医学科学院肿瘤医院
新型PI3Kδ抑制剂Linperlisib治疗复发和/或难治性外周T细胞淋巴瘤患者的Ib期研究
讲者：邱录贵
单位：中国医学科学院血液病医院
First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Efficacy of humanised anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease
讲者：邓琦
单位：天津市第一中心医院
伊布替尼联合利妥昔单抗治疗接受过二个及以上方案化疗、伴有 CD79A/B 和MYD88 基因突变(或 CD79B 基因突变)的复发难治弥漫大B细胞淋巴瘤患者的II期、多中心临床研究
讲者：石远凯
Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma: A multicenter, randomized, double-blind, placebo-controlled, phase III trial
奥希替尼治疗EGFR-TKI进展后不同T790M表达时非小细胞肺癌脑膜转移的疗效
讲者：王燕
瑞基奥仑赛注射液（Relmacabtagene Autoleucel）治疗复发/难治性大b细胞淋巴瘤：RELIANCE研究的1年随访结果
A phase 2 study of surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: an updated analysis
讲者：沈琳
